Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has shared an announcement.
On November 20, 2025, Shuttle Pharmaceuticals Holdings, Inc. finalized an Asset Purchase Agreement with its subsidiary and other parties, acquiring substantial assets and liabilities from a Canadian corporation. The transaction involved a cash payment of $3 million on the closing date, with additional payments and potential milestone-based contributions outlined in the agreement. This strategic acquisition is expected to enhance Shuttle Pharmaceuticals’ capabilities in drug discovery, leveraging advanced AI models to accelerate the process, which may strengthen its position in the pharmaceutical industry.
Spark’s Take on SHPH Stock
According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.
Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.
To see Spark’s full report on SHPH stock, click here.
More about Shuttle Pharmaceuticals Holdings, Inc.
Average Trading Volume: 303,848
Technical Sentiment Signal: Sell
Current Market Cap: $2.13M
For detailed information about SHPH stock, go to TipRanks’ Stock Analysis page.